ANI PHARMACEUTICALS INC (ANIP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$311.2M
Cash & Equivalents
$58.4M
Quarterly Burn Rate
$1,867M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-30 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04674969 | Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature | OTHER | Recruiting | 5,000 |
| NCT03887455 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | PHASE3 | Active Not Recruiting | 1,906 |
| NCT06659549 | A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non... | PHASE2 | Recruiting | 110 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.